Based in Zug (Switzerland), Lallemand Pharma International (LPI) is dedicated exclusively to the clinical studies, registration, marketing and sales of pharmaceutical products based on high quality mechanical bacterial lysates produced by Lallemand.
The primary objective of LPI is to develop and sell a range of bacterial lysates (Ismigen®, Immubron®, Bromunyl®, Respibron® and Bactovax®) produced at Lallemand's Saint-Simon facility in France. The specificity of these lysates is that they are produced from a complete range of pathogenic bacteria that are inactivated through mechanical lysis. This original and unique process gives the drug a far stronger immunogenic power than other lysates currently on the market.
The company's key product - Ismigen® - is recommended in the prophylaxis and treatment of chronic and acute respiratory infections and diseases. Backed by numerous clinical trials, Ismigen® is already registered and successfully marketed in numerous countries.